

Kidney Suite - Committee Meeting 6 Day 1
Date: 11th November 2019

Location: NICE offices London

Minutes: Final

Committee members present:		
Anthony Wierzbicki (AW)	Chair	Present for all
Clare Allinson (CA)	Advanced Nurse Practitioner	Present for all
Virginia Aylett (VA)	Consultant in Medicine for the Elderly	Present for all
Tristan Barrett (TB)	NHS Honorary Consultant Radiologist University Lecturer	Present for all
Roy Connell (RC)	Paediatric Renal Nurse	Present for all
Jan Dudley (JD)	Consultant Paediatric Nephrologist	Present for all
Deepa Kariyawasam (DK)	Senior Renal Dietitian	Present for all
Arif Khwaja (AK)	Consultant Nephrologist	Present from partway through item 3
Fiona Loud (FL)	Lay Member	Present for items 1-5
Catherine Pogson (CP)	Renal Pharmacist	Present until partway through item 5

In attendance:		
Catherine Baden-Daintree (CB)	Editor	Present until item 3
Chris Carmona (CC)	Senior Technical Analyst	Present for all
Justine Karpusheff (JK)	Commissioning Manager	Present for items 1-3
Yolanda Martinez (YM)	Analyst - Guideline Updates Team	Present for all
Vonda Murray (VM)	Project Manager	Present for all
Hannah Nicholas (HN)	Technical Analyst – Health Economics	Present for all
Gabriel Rogers (GR)	Technical Adviser – Health Economics	Present for all
Shreya Sukla (SS)	Technical Analyst	Present for all
Susan Spiers (SSP)	Associate Director	Present for all

Kidney Suite GComm 6 minutes

Apologies:	
Tara Bashford	Lay member
Ivan Benett	GP
Grainne Connelly	Senior Renal Dietitian
Andrew Lewington	Consultant Renal Physician
Rajib Pal	GP
Nicola Thomas	Professor of Kidney Care

Observers:	
Rui Martins	Assistant Technical Analyst

1.

- **Welcome**
- **Objectives**
- **Declarations of interest**
- **Minutes of the last meeting**

The Chair welcomed the Committee members and attendees to the 1st day of the 6th committee meeting on Kidney Injury & Disease Update.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included:

- Acute Kidney Injury stakeholder comments review
- Agree review protocols
- Review and discussion of the evidence for chronic kidney disease and what eGFR threshold should trigger investigation of anaemia due to chronic kidney disease
- Review and discussion of the evidence for people with chronic kidney disease on dialysis, which phosphate binder, calcium and non-calcium based, is most effective in managing serum phosphate and its associated outcomes

The Chair asked all committee members to verbally declare any interests that have arisen since the last meeting. The Chair and senior members of the Developer team noted that the interests previously declared, and any new interests did not prevent the attendees from fully participating in the meeting. New interests are noted below;

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Anthony Wierzbicki	Chair - Consultant Chemical Pathologist, Guys &	Site clinical trial co-investigator:	In-direct financial	Declare and participate Rationale: Not

Kidney Suite GComm 6 minutes

	St Thomas' NHS Trust, London	cardiovascular disease VESALIUS study (Amgen; Evolocumab)		covered by the scope of the guideline.
Virginia Aylett	Consultant in Medicine for the Elderly, St James's University Hospital, Leeds	Attended British Geriatrics Society meeting in Leicester	Non-financial personal and professional	Declare and participate Rationale: Not specific to any topic covered by the scope
Jan Dudley	Consultant Paediatric Nephrologist, Bristol Royal Hospital for Children	Co-applicant ATTOMic (access to transplantation and outcome measures in children)	Indirect financial	Declare and participate Rationale: Not specific to any topic covered by the scope
Jan Dudley	Consultant Paediatric Nephrologist, Bristol Royal Hospital for Children	Chair, Paediatric Subgroup of NHSBT Kidney Advisory Group.	Non-Financial personal and professional	Declare and participate Rationale: Not specific to any topic covered by the scope
Catherine Pogson	Renal Pharmacist, Portsmouth Hospitals NHS Trust	Attended (self-funded) renal pharmacy group conference in September. The conference was sponsored by; Astella, Astrazeneca, Chiesi, Napp, Olsuka, Sandoz, Stanningley, Syner-Med, Vifor,	Non-Financial personal and professional	Declare and participate Rationale: Attendance does not present a conflict for membership of the committee

The Chair asked the Committee if it wanted any changes made to the minutes of the last

Kidney Suite GComm 6 minutes

<p>meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.</p>
2. Acute Kidney Injury (AKI) post consultation
<p>The Chair introduced CC, Senior Technical Analyst, who presented some of the comments received from stakeholders during consultation. The Chair thanked CC for their presentation.</p>
3. Next set of review protocols
<p>CC facilitated a discussion on what should be included in 3 protocols. The Chair thanked CC for facilitating the discussion.</p>
4. RQ6.1: For people with CKD, what eGFR threshold should trigger investigation of anaemia being due to CKD?
<p>A change to the agenda item, from RQ7.1 to RQ6.1</p> <p>The Chair introduced SS, Technical Analyst, who gave a presentation on what eGFR threshold should trigger investigation of anaemia being due to CKD for people with CKD. The Chair thanked SS for their presentation.</p>
5. Chronic kidney disease: management of hyperphosphatemia
<ul style="list-style-type: none">• RQ5.2 Hyperphosphatemia in CKD stage 5 (on dialysis) – clinical evidence review
<p>The Chair introduced YM, Technical Analyst who gave a presentation on the clinical evidence for people with stage 5 CKD who are on dialysis, which phosphate binder, calcium and non-calcium based, is most effective in managing serum phosphate and its associated outcomes. The Chair thanked YM for their presentation.</p>
6. AOB
<p>Two items of AOB was raised by CC;</p> <p>CC asked the committee for advice on an area of the CKD guideline that is not part of this update.</p> <p>CC asked the committee a question regarding cystatin C-based equations to estimate GFR as a measurement of kidney function.</p>
7. Summary and next steps
<p>The Chair thanked the committee for their time and contribution to the meeting.</p>

Kidney Suite GComm 6 minutes

Kidney Suite - Committee Meeting 6 Day 2

Date: 12th November 2019

Location: NICE offices London

Minutes: Draft

Committee members present:		
Anthony Wierzbicki (AW)	Chair	Present for all
Clare Allinson (CA)	Advanced Nurse Practitioner	Present for all
Virginia Aylett (VA)	Consultant in Medicine for the Elderly	Present for all
Roy Connell (RC)	Paediatric Renal Nurse	Present for all
Grainne Connelly (GC)	Senior Renal Dietitian	Present for all
Jan Dudley (JD)	Consultant Paediatric Nephrologist	Present for all
Deepa Kariyawasam (DK)	Senior Renal Dietitian	Present for all
Arif Khwaja (AK)	Consultant Nephrologist	Present for all
Andrew Lewington (AL)	Consultant Renal Physician	Present from item 3
Catherine Pogson (CP)	Renal Pharmacist	Present for all
Nicola Thomas (NT)	Professor of Kidney Care	Present until item 5

In attendance:		
Chris Carmona (CC)	Senior Technical Analyst	Present for all
Justine Karpusheff (JK)	Commissioning Manager	Present for all
Yolanda Martinez (YM)	Analyst - Guideline Updates Team	Present for all
Vonda Murray (VM)	Project Manager	Present for all
Hannah Nicholas (HN)	Technical Analyst – Health Economics	Present for all
Gabriel Rogers (GR)	Technical Adviser – Health Economics	Present for all
Susan Spiers (SS)	Associate Director	Present for all

Kidney Suite GComm 6 minutes

Apologies:	
Catherine Baden-Daintree	Editor
Tara Bashford	Lay member
Tristan Barrett	NHS Honorary Consultant Radiologist University Lecturer
Ivan Benett	GP
Fiona Loud	Lay Member
Rajib Pal	GP
Shreya Sukla	Technical Analyst

Observers:	
Rui Martins	Technical Analyst – Health Economics

1.

- Welcome
- Objectives
- Declarations of interest

The Chair welcomed the Committee members and attendees to the 2nd day of the 6th meeting on Kidney Injury & Disease Update.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included:

- Health Economics modelling on chronic kidney disease (CKD stage 5) management of hyperphosphatemia
- Chronic kidney disease: management of hyperphosphatemia (CKD stage 4 and 5), clinical evidence and health economics

The Chair asked all committee members to verbally declare any interests that have arisen since the last meeting. The Chair and senior members of the Developer team noted that the interests previously declared, did not prevent the attendees from fully participating in the meeting. New interests are noted below;

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Andrew Lewington	Consultant Renal Physician, St James's University Hospital, Leeds	Attended the American Society of Nephrology conference 9th November	Non-Financial personal and professional	AKI was covered, in the presentation. Attendance does not present a conflict for

Kidney Suite GComm 6 minutes

		2019, self-funded. Attended a session on global impact of kidney disease and a presentation on contrast induced AKI		membership of the committee
2. Chronic kidney disease: management of hyperphosphatemia <ul style="list-style-type: none"> RQ5.2 Hyperphosphatemia in CKD stage 5 (on dialysis) - health economics 				
<p>The Chair introduced GR, Technical Adviser – Health Economics, and HN, Technical Analyst – Health Economics who gave a presentation on health economics and hyperphosphatemia, those with stage 5 CKD who are on dialysis, which phosphate binder, calcium and non-calcium based, is most effective in managing serum phosphate and its associated outcomes). The Chair thanked GR and HN for their presentation.</p>				
3. Chronic kidney disease: management of hyperphosphatemia <ul style="list-style-type: none"> RQ5.1 Hyperphosphatemia in CKD stages 4 and 5 (not on dialysis) – clinical evidence review and health economics 				
<p>The Chair introduced YM Technical Analyst, who gave a presentation on the clinical evidence for people with stage 4 or 5 CKD who are not on dialysis, which phosphate binder, calcium and non-calcium based, is most effective in managing serum phosphate and its associated outcomes.</p> <p>GR, Technical Adviser – Health Economics, and HN, Technical Analyst – Health Economics provided a presentation on the health economic evidence for people with stage 4 or 5 CKD who are not on dialysis, which phosphate binder, calcium and non-calcium based, is most effective in managing serum phosphate and its associated outcomes. The Chair thanked GR, HN, and YM for their presentation.</p>				
4. Committee discussion and recommendations				
<p>The committee discussed the clinical and health economic information for people with stage 4 or 5 CKD who are not on dialysis, which phosphate binder, calcium and non-calcium based, is most effective in managing serum phosphate and its associated outcomes.</p>				
5. AOB				
<p>CC facilitated a discussion on what should be included in 4 protocols. The Chair thanked CC for facilitating the discussion.</p>				
6. Summary and next steps				
<p>The Chair thanked the committee for their time and contribution to the meeting. The venue, date and time of the next meeting was confirmed</p>				

Kidney Suite GComm 6 minutes

Date of next meeting: Thursday 30th and Friday 31st January 2020 – (London)

Location of next meeting: Thursday 30th January – venue to be confirmed in London

Friday 31st January – NICE Office London